TheEdgeResearch
Home / Stocks / KNBIF

Kane Biotech Inc. (KNBIF)

OTC Healthcare Biotechnology
$0.02 ▲ +0.00%
Market Cap
$4.8M
Sector
Healthcare
Industry
Biotechnology
Beta
0.31
52-Wk Range
0.01038-0.0338
CEO
Robert Huizinga
Country
CA
Currency
USD

Kane Biotech Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Winnipeg, MB, CA. The stock last traded at $0.02, up 0.00% on the session, giving a market capitalisation of $4.8M. On trailing twelve-month figures it carries a trailing P/E of -2.05, a net margin of -6980.2%. Its beta of 0.31 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-2.05
Price / Sales
158.88
Price / Book
-6.19
EV / EBITDA
-2.36
Gross margin
-503.1%
Operating margin
-8113.8%
Net margin
-6980.2%
Return on equity
—
Debt / equity
-1.98
Current ratio
0.61
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
20
IPO date
2007-08-07
Headquarters
Winnipeg, MB, CA
About Kane Biotech Inc.

Headquartered in Winnipeg, Canada, Kane Biotech Inc. is a biotechnology firm established in 2001, focusing on the research, development, and global commercialization of innovative technologies and products engineered to prevent and remove microbial biofilms. The company's diverse portfolio features pet dental hygiene solutions marketed as StrixNB and bluestem, alongside DispersinB for both animal and human wound care. They also provide Alosera brand shampoos for dogs, cats, and horses, and Aledex for medical device coatings. Additional offerings include DermaKB scalp care products, Coactiv+ wound care items, and other specialized products under the goldstem, silkstem, and DermaKB Biofilm brand names.

Comparable companies

Kane Biotech Inc. is most often compared with the following Healthcare names:

BIXTBUDZBVAXFBZYRFAMDFGLWLFMYNDFPMEDFTHERTXTM
More research on KNBIF
KNBIF technical analysis KNBIF TheEdge Score Compare against peers
Open full interactive analysis & DCF →